Page 120 - 2019_10 resto del Mondo_web

M. Chapellier et al.
arthritis, IL-17 production and Th2
response. Eur J Immunol. 2008;38(12):
3450-3458.
14. Miller PG, Al-Shahrour F, Hartwell KA, et
al. In Vivo RNAi Screening Identifies a Leukemia-Specific Dependence on Integrin Beta 3 Signaling. Cancer Cell. 2013; 24(1):45-58.
15. Puram RV, Kowalczyk MS, de Boer CG, et al. Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell. 2016;165(2):303-316.
16. Wang Y-Y, Zhao L-J, Wu C-F, et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2011;108(6):2450-2455.
17. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and sig- naling. Semin Immunol. 2006;18(5):263- 275.
18. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med. 2005;201(9):1375-1383.
19. Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell prolif- eration. Cell Death Differ. 2005;12(6):637- 648.
20. Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
21. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209–2221.
22. Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clini- co-pathologic and genetic features. Leukemia. 2016;30(11):2160–2168.
23. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monoso- mal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121.
24. Podolin PL, Callahan JF, Bolognese BJ, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4- fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther. 2005;312(1):373-381.
25. Grüner BM, Schulze CJ, Yang D, et al. An in vivo multiplexed small-molecule screening
tor to leukaemia stem cell initiated by
MLL–AF9. Nature. 2006;442(7104):818- 26. Hahne M, Kataoka T, Schroter M, et al. 822.
platform. Nat Methods. 2016;13(10):883-
889.
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185-1190.
27. García-Castro A, Zonca M, Florindo- Pinheiro D, et al. APRIL promotes breast tumor growth and metastasis and is associ- ated with aggressive basal breast cancer. Carcinogenesis. 2015;36(5):574-584.
28. Wang R, Guo Y, Ma H, et al. Tumor necro- sis factor superfamily member 13 is a novel biomarker for diagnosis and prognosis and promotes cancer cell proliferation in laryn- geal squamous cell carcinoma. Tumour Biol. 2016;37(2):2635-2645.
29. Chiu A, Xu W, He B, et al. Hodgkin lym- phoma cells express TACI and BCMA receptors and generate survival and prolif- eration signals in response to BAFF and APRIL. Blood. 2007;109(2):729-739.
30. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2):703-710.
31. Quinn J, Glassford J, Percy L, et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D- type cyclin group and translocation status. Blood. 2011;117(3):890-901.
32. Tai Y-T, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225-3236.
33. Moreaux J, Veyrune J-L, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer. 2009; 9:83.
34. Varfolomeev E, Kischkel F, Martin F, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol. 2004;24(3):997-1006.
35. Castigli E, Scott S, Dedeoglu F, et al. Impaired IgA class switching in APRIL-defi- cient mice. Proc Natl Acad Sci U S A. 2004;101(11):3903-3908.
36. Bonci D, Musumeci M, Coppola V, et al. Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity. Haematologica. 2008;93(12):1899-1902.
37. Bolkun L, Lemancewicz D, Jablonska E, et al. The impact of TNF superfamily mole- cules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features. Ann Hematol. 2015; 94(1):35-43.
38. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progeni-
39. Jablonska E, Wawrusiewicz-Kurylonek N, Garley M, et al. A proliferation-inducing ligand (APRIL) in neutrophils of patients with oral cavity squamous cell carcinoma. Eur Cytokine Netw. 2012;23(3):93-100.
40. Schwaller J, Schneider P, Mhawech- Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteo- glycans correlates with human B-cell lym- phoma aggressiveness. Blood. 2007; 109(1):331-338.
41. Matthes T, Dunand-Sauthier I, Santiago- Raber M-L, et al. Production of the plasma- cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118(7):1838-1844.
42. Matthes T, McKee T, Dunand-Sauthier I, et al. Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow. Leukemia. 2015;29(9):1901-1908.
43. Kern C, Cornuel J-F, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103 (2):679-688.
44. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148-3157.
45. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004;172(5):3268-3279.
46. Roth W, Wagenknecht B, Klumpp A, et al. APRIL, a new member of the tumor necro- sis factor family, modulates death ligand- induced apoptosis. Cell Death Differ. 2001;8(4):403-410.
47. Kuo H-P, Wang Z, Lee D-F, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kappaB. Cancer Cell. 2013;24(4): 423-437.
48. Bosman MCJ, Schepers H, Jaques J, et al. The TAK1-NF-kappaB axis as therapeutic target for AML. Blood. 2014;124(20):3130- 3140.
49. Ågerstam H, Hansen N, von Palffy S, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 2016;128(23):2683-2693.
50. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6853-6866.
2016
haematologica | 2019; 104(10)